-1753895561853.webp&w=3840&q=75)
2025 NOSCM | Hodgkin’s Disease: Novel Advances in Early and Advanced Stages
Overview
Dr. Jose Sandoval-Sus reviewed Hodgkin lymphoma advances, noting 80% cure rates and a shift to reduce toxicity. PET scans may be avoidable in early-stage cases. Trials like ECHELON-1, SWOG S1826, and HD21 support brentuximab and nivolumab combos. Future care focuses on genetics and MRD-guided strategies.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Jose Sandoval-Sus, MD
Date of Release
July 30th, 2025
-1753895653633.webp&w=3840&q=75)
-1753895472875.webp&w=3840&q=75)